Ligand Pharmaceuticals Incorporated

LGND

US53220K5048

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 16/07/2024 am IST			5-day change	1st Jan Change
96.67 ^USD	-2.76%		+11.27%	+35.35%

08/07	Ligand to Acquire Apeiron for $100 Million in Cash, Plus Up to $28 Million Based on Royalties	MT
08/07	Ligand Pharmaceuticals Incorporated Revises Earnings Guidance for the Year 2024	CI

Ligand Pharmaceuticals Incorporated Revises Earnings Guidance for the Year 2024

July 08, 2024 at 04:30 pm IST

Ligand Pharmaceuticals Incorporated revised earnings guidance for the year 2024. The company is increasing its 2024 revenue guidance to be in the range of $140 million to $157 million (previously $130 million to $142 million).

Latest news about Ligand Pharmaceuticals Incorporated

Ligand to Acquire Apeiron for $100 Million in Cash, Plus Up to $28 Million Based on Royalties	08/07	MT
Ligand Pharmaceuticals Incorporated Revises Earnings Guidance for the Year 2024	08/07	CI
Ligand Pharmaceuticals Incorporated entered into an agreement to acquire APEIRON Biologics AG for $128 million.	08/07	CI
Invios GmbH announced that it expects to receive $4 million in funding from Ligand Pharmaceuticals Incorporated	08/07	CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) added to Russell 2000 Defensive Index	01/07	CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell 3000 Growth Index	01/07	CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) added to Russell 2000 Value-Defensive Index	01/07	CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell 3000E Growth Index	01/07	CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell 2000 Growth Index	01/07	CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell 2500 Growth Index	01/07	CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell Small Cap Comp Growth Index	01/07	CI
Ligand Pharmaceuticals' Partner Gets US FDA Approval for Ohtuvayre to Treat Chronic Obstructive Pulmonary Disease	27/06	MT
Merck Receives FDA Approval for Capvaxive, Triggers $2 Million Payment for Ligand Pharmaceuticals	18/06	MT
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE? (Pneumococcal 21-valent Conjugate Vaccine) for Adults	18/06	CI
Ligand Pharmaceuticals Insider Sold Shares Worth $830,449, According to a Recent SEC Filing	14/05	MT
Tranche Update on Ligand Pharmaceuticals Incorporated's Equity Buyback Plan announced on August 8, 2023.	09/05	CI
Sector Update: Health Care Stocks Softer Late Afternoon	09/05	MT
Ligand Pharmaceuticals Shares Rise After Q1 Adjusted Earnings, Revenue Beat Views	08/05	MT
Transcript : Ligand Pharmaceuticals Incorporated, Q1 2024 Earnings Call, May 07, 2024	08/05
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Posts Q1 Revenue $31M, vs. Street Est of $27.9M	08/05	MT
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q1 EPS $1.20, vs. Street Est of $0.83	08/05	MT
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Ligand Pharmaceuticals Incorporated Reaffirms Earnings Guidance for the Year 2024	08/05	CI
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading	07/05	MT
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	07/05	MT

Chart Ligand Pharmaceuticals Incorporated

Duration

Period

Chart Ligand Pharmaceuticals Incorporated

More charts

Company Profile

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.

Sector

Pharmaceuticals

Calendar

05/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Ligand Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

96.67 USD

Average target price

117.8 USD

Spread / Average Target

+21.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LIGAND PHARMACEUTICALS INCORPORATED	+35.35%	173.65Cr
ELI LILLY AND COMPANY	+63.05%	86TCr
NOVO NORDISK A/S	+39.03%	63TCr
JOHNSON & JOHNSON	-4.78%	36TCr
MERCK & CO., INC.	+17.52%	32TCr
ABBVIE INC.	+8.43%	30TCr
ASTRAZENECA PLC	+13.34%	24TCr
ROCHE HOLDING AG	+5.03%	23TCr
NOVARTIS AG	+16.24%	23TCr
AMGEN INC.	+14.63%	18TCr

Other Pharmaceuticals